维生素D缺乏和2型糖尿病视网膜病变风险度的相关性研究

摘要 目的：是探讨维生素D缺乏与2型糖尿病（T2DM）患者视网膜病变（DR）发生风险度的关系。方法：选取2020年12月至2022年8月在新疆医科大学第二附属医院内分泌科住院的2型糖尿病患者作为研究对象。将209名患者根据眼底检查分为DR组（n=50）和正常眼底（NDR）组（n=159）。比较各组患者一般资料、实验室检查指标;采用Spearman分析法分析病程、FBG、HbAlC、25(OH)D与DR的相关性,采用Pearson分析居住地（城镇）、与维生素D缺乏、SBP与DR的相关性,采用Logistics回归分析DR发生的影响因素,比较各组患者维生素D缺乏、病程、FBG、HbA1c及25(OH)D对DR的预测价值。结果：DR组的居住地（农村）、FBG、HbA1c、病程等均大于NDR组,25(OH)D水平低于NDR组,DR组维生素D缺乏率大于NDR组,差异有统计学意义（P＜0.05）。Pearson相关性分析结果表明DR与居住地（城镇）呈负相关（P＜0.05）,与SBP、维生素D缺乏呈正相关（P＜0.05）;Spearman相关分析表明DR与25(OH)D呈负相关（P＜0.05）,与病程、空腹血糖和糖化血红蛋白等呈正相关（P＜0.05）。Logistic回归分析结果显示,维生素D缺乏、病程、FBG、HbA1c为DR的独立危险因素（P＜0.05）,维生素D缺乏的T2DM患者DR发病风险是维生素D不缺乏者的22.019倍（OR=22.019,95%CL 2.119~228.771,P＜0.05）。受试者工作特征（ROC）曲线分析显示,病程、FBG、HbA1c、25(OH)D作为联合变量可有效预测DR,ROC曲线下面积为0.924。结论：25(OH)D与DR呈负相关,维生素D缺乏可能与T2DM患者DR的发生有关。     

1,25—二羟基维生素D3的免疫调节机能

1,25-二羟基维生素D_3是人们熟悉的调节钙磷代谢的重要激素,它可抑制淋巴细胞增殖和抗体生成,诱导巨噬细胞的分化及细胞表面主要组织相容性抗原的表达,是一种新的免疫调节激素。     

1,25—二羟维生素D3的免疫调节作用

１,２５（ＯＨ）２Ｄ３是维生素Ｄ３的形式,其生物效应是由１,２５（ＯＨ）２Ｄ３受体（ＶＤＲ）介导的。单核细胞、激活的淋巴细胞等免疫系统细胞均有ＶＤＲ的表达,１,２５（ＯＨ）２Ｄ３对免疫系统功能有重要调节作用,主要表现于：在分子水平上抑制白细胞介素２（ＩＬ－２）、γ－干扰素（ＩＮＦ－γ）及粒单系集落刺激因子（ＧＭ－ＣＳＦ）等细胞因子的表达;细胞水平上调节免疫系统细胞的增殖分化及其免疫功能;在整体水平     

补充维生素D和钙无法预防老人骨折

补充维生素D和钙一直被认为是预防老年人骨折最有效和简便的方法,而且从来没有人对此表示过怀疑。但是英国科学家的两项最新研究显示,补充钙和维生素D似乎不能预防老年人骨折。     

孕妇维生素D缺乏与妊娠期糖尿病的相关性分析

目的:调查孕妇妊娠早期维生素D水平及其影响因素,探讨维生素D缺乏与妊娠期糖尿病的相关性。方法:选取2012年7月至2013年4月在上海交通大学医学院附属新华医院产科正规产检并分娩的非孕前糖尿病孕妇,在其建卡初检时采用电化学发光免疫技术测定血清25(OH)D3水平;妊娠24-28周行糖筛查及糖耐量试验,诊断是否为妊娠期糖尿病GDM。收集并整理孕妇年龄,孕前体重指数BMI、维生素D测定孕周与测定季节、孕期维生素D补充情况等信息。结果:1000例孕妇中,GDM发病率为11.5%,维生素D缺乏比例占67.4%;其中,约有54%孕妇常规补充复合维生素,约含维生素400 IU/天,10%孕妇常规补充维生素D。GDM孕妇25(OH)D3水平显著低于正常对照组(P=0.007)。维生素D缺乏孕妇发生GDM的风险是维生素D水平较高组的1.944倍,且在秋冬季更易发生GDM。可以考虑在孕14-16周进行维生素D水平的早期测定。结论:孕妇维生素D缺乏十分普遍。妊娠早期孕妇低维生素D水平可能增加孕妇胰岛素抵抗及孕期发生GDM的发生风险。     

维生素 D 与2型糖尿病的关系

维生素D一直被称为抗佝偻病因子或日光维生素,如今,维生素D缺乏已经成为全球性的健康问题。目前越来越多的证据表明维生素D除了参与骨代谢外,在2型糖尿病的发生及发展的几条关键通路上发挥重要的调节作用,但基于人群的研究得到的结论并不一致。本文将重点探讨维生素D与T2DM的关系。     

糖尿病患者维生素D的膳食摄入状况调查

目的：了解我国糖尿病患者群体维生素D的膳食摄入状况,为维生素D缺乏的防治提供依据。方法：收集2014年8月—2014年11月的糖尿病住院患者和门诊患者,收集患者年龄、性别、身高、体重、伴有基础疾病等基本资料,按年龄分成人组（26~64周岁）和老年人组（＞65周岁）。采用24h膳食回顾法调查就诊前一天的膳食情况,参考美国农业部发布的食物成分表,计算出膳食总能量和维生素D的摄入量。同时采用简化食物频率法调查过去1个月内患者高维生素D食物的进食频率,同时调查含维生素D膳食补充剂或功能性食品的摄入。结果：糖尿病患者机体维生素D的缺乏普遍存在,且更加严重,成人组和老年人组血清维生素D水平分别为409±114、362±155nmol/L。由于营养治疗限制了富维生素D食物的应用,糖尿病患者维生素D的总摄入（2717±913、3326±1113U）明显低于同龄正常人每日推荐量（400、600U）,这对糖尿病维生素D缺乏的防治提出了挑战。结论：糖尿病患者维生素D摄入明显不足,体内维生素D普遍缺乏,为防治维生素D缺乏,除户外活动动外可能需要膳食补充剂或强化食品额外补充。     

维生素D受体最新研究进展

维生素D受体(vitamin D receptor,VDR)是一种核转录因子,通过与配体特异结合,调控多种基因的表达,从而调节多种生命活动的进行.本文总结了近年来VDR的研究进展,主要包括VDR的作用机制、VDR行使功能所需共激活子及共抑制子、VDR在生长分化、免疫调节和抑制肿瘤等方面的作用及VDR配体类似物在药物开发研究领域的最新进展.     

维生素D与高血压关系的研究进展

众所周知维生素D(VitD)在钙、磷代谢及骨重建中具有重要的作用。而近年来许多研究发现VitD与高血压、心力衰竭、缺血性心脏病和脑卒中等心血管事件的发生呈负相关,其具体机制尚不完全清楚,经过补充VitD可以预防或治疗高血压,VitD缺乏参与了高血压的形成,成了最近争论的焦点。故本文将对VitD和高血压相互关系的研究进展做一综述,为高血压的防治提供新的理论依据。     

脂溶性维生素A、D、E与妊娠期糖尿病的相关性分析

目的:探讨妊娠期糖尿病(gestational diabetes mellitus,GDM)孕妇血清中维生素A、25-羟基维生素D、维生素E的水平及其临床意义。方法:选取在大连大学附属中山医院就诊并诊断为GDM的孕妇1000例为实验组;另选取无GDM孕妇1000例为对照组。采用反向高频液相色谱荧光法(high-performance liquid chromatography,HPLC)测定其血清维生素A、E水平;高效液相色谱液相色谱串联质谱法(high-performance liquid chromatography tandem mass spectrometer,HPLC-AS/MS)测定血清25-羟基维生素D水平。结果:GDM孕妇血清中维生素A水平与无GDM孕妇比较差异无统计学意义(P>0.05);GDM孕妇血清25-羟基维生素D水平明显低于对照组(P<0.05);GDM孕妇血清维生素E水平明显高于对照组(P<0.05)。GDM孕妇血清25-羟基维生素D水平与血清维生素E水平呈显著负相关(r=-0.351,P<0.05)。结论:GDM孕妇血清25-羟基维生素D水平低,维生素E水平高,且两者有一定相关性,可能共同参与了GDM的发生。     

抗炎药物用于 2 型糖尿病预防与治疗的研究进展

近年来,炎症反应在2型糖尿病发病机制中的作用受到广泛关注。流行病学和实验动物研究均证明,肥胖及其诱发的慢性炎症 与2型糖尿病有密切的关系。基于诸多临床流行病学调查及大型前瞻性研究结果,目前已形成对糖尿病胰岛素耐受性的炎症发病机制的 共识。到目前为止,多种具有抗炎作用机制的活性小分子药物已经上市或进入临床研究阶段,这些药物单独治疗或与传统降糖药物联用 均取得了令人满意的效果,显示了糖尿病抗炎治疗的前景。主要综述近年来慢性炎症在2型糖尿病发生发展过程中的分子机制以及抗炎 药物用于治疗2型糖尿病的研究进展     

2型糖尿病与骨质疏松多因素影响的研究进展

摘要：随着人们生活水平的不断提高以及国人寿命的不断延长,2型糖尿病（T2DM）＆骨质疏松（OP）的发病率在全世界范围呈现增高趋势。T2DM并发OP受着性别、年龄、病程、高血糖、糖基化终末产物过多、胰岛素、慢性并发症、肥胖、瘦素、饮食、运动及降糖药物的多种因素影响。骨质疏松症作为糖尿病慢性并发症之一,已严重影响患者的生活质量,T2DM患者在控制血糖同时,应预防其相关因素,定期进行骨密度测定是极为重要的,临床医生应给予高度重视,进行早期预防和治疗。     

表观遗传学在2型糖尿病领域的研究进展

2型糖尿病(T2DM)是由遗传和环境因素共同作用而形成的多基因遗传复杂性疾病,病因和发病机制至今未完全明了.最新研究发现,表观遗传学直接或间接参与糖尿病的发病,影响胰岛β细胞的发育和分泌功能,降低机体对胰岛素的敏感性等,最终导致T2DM的发生.因此,基因的表观遗传修饰如microRNA、DNA甲基化及组蛋白修饰在糖尿病的发生发展中起到了重要的作用,对其深入研究将为T2DM预防和治疗提供新的思路.     

Effect of Metformin Therapy on Vitamin D and Vitamin B12 Levels in Patients with Type 2 Diabetes Mellitus

ObjectiveTo determine the effect of metformin on 25-hydroxyvitamin D [25(OH)D] and vitamin B₁₂ levels in patients with type 2 diabetes mellitus.MethodsWe performed a retrospective review of medical records of patients treated between 2003 and 2009 at Loyola University Medical Center, Maywood, Illinois, in both ambulatory primary care and endocrinology clinics. The study cohort consisted of 706 patients with type 2 diabetes mellitus who were 20 to 93 years old (mean age, 63 ± 13) and had a mean body mass index of 33.1 kg/m². Of these patients, 42% were treated with metformin, and 34% had been diagnosed with osteoporosis or osteopenia.ResultsPatients taking metformin had statistically significant lower vitamin B₁₂ levels than those not receiving metformin (P < .0001; 95% confidence interval [CI] = − 220 to − 84 pg/mL). No statistically significant difference was found between users and nonusers of metformin in regard to 25(OH)D levels when adjusted for variables (P = .297; 95% CI for mean difference = − 0.7 to 2.2 ng/mL). Metformin use did not adversely affect successful treatment of vitamin D deficiency in this patient population as a whole, nor did it affect the subgroup with osteoporosis (P = .956). The patients with osteoporosis had statistically significant lower baseline 25(OH)D levels in comparison with those without osteoporosis, when adjustments were made for all variables (P = .003; 95% CI = 0.7 to 3.5 ng/ mL).ConclusionThis study confirms the higher prevalence of vitamin B₁₂ deficiency in metformin-treated patients with type 2 diabetes than in those not treated with metformin. This study also suggests that vitamin D deficiency is not a clinical concern among metformin-treated patients with type 2 diabetes and that metformin does not negatively affect treatment of vitamin D deficiency in these patients. (Endocr Pract. 2012;18:179–184)     

BNP及NT-proBNP与2型糖尿病关系的研究进展

BNP及NT-proBNP是诊断心衰的重要指标。近年来BNP及NT-proBNP与2型糖尿病关系的研究有了新的进展。我们收集近年来国内外关于2型糖尿病中BNP及NT-proBNP的相关文献并进行研究。结果显示2型糖尿病合并冠心病、高血压、糖尿病肾病患者BNP或NT-proBNP有升高趋势。单纯2型糖尿病及糖尿病视网膜病变患者以及低血糖患者BNP或NT-proBNP差异无统计学意义。高血压、年龄、性别、体重指数、肾功能及心脏结构功能改变是2型糖尿病患者BNP及NT-proBNP的影响因素。降糖药物对2型糖尿病患者BNP及NT-proBNP水平的研究尚少,糖尿病病程、FPG以及HbA1c对BNP及NT-proBNP的影响尚存在争议。BNP及NT-proBNP升高对2型糖尿病合并冠心病、高血压、糖尿病肾病患者病情评估,预后判断及诊治具有非常重要的意义。降糖药物、糖尿病病程、FPG以及HbA1c对BNP及NT-proBNP的影响需要进一步研究。     

Interactions between Serum Vitamin D Levels and Vitamin D Receptor Gene FokI Polymorphisms for Renal Function in Patients with Type 2 Diabetes

Background

We aimed to examine associations among serum 25-hydroxyvitamin D (25OHD) levels, 1,25-dihyroxyvitamin D (1,25OHD) levels, vitamin D receptor (VDR) polymorphisms, and renal function based on estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes.

Methods

In a cross-sectional study of 410 patients, chronic kidney disease (CKD) stage assessed by eGFR was compared with 25OHD, 1,25OHD, and VDR FokI (rs10735810) polymorphisms by an ordered logistic regression model adjusted for the following confounders: disease duration, calendar month, use of angiotensin converting enzyme inhibitors/angiotensin receptor blockers or statins, and serum calcium, phosphate, and intact parathyroid hormone levels.

Results

1,25OHD levels, rather than 25OHD levels, showed seasonal oscillations; peak levels were seen from May to October and the lowest levels were seen from December to February. These findings were evident in patients with CKD stage 3∼5 but not stage 1∼2. eGFR was in direct proportion to both 25OHD and 1,25OHD levels (P<0.0001), but it had stronger linearity with 1,25OHD (r = 0.73) than 25OHD (r = 0.22) levels. Using multivariate analysis, 1,25OHD levels (P<0.001), but not 25OHD levels, were negatively associated with CKD stage. Although FokI polymorphisms by themselves showed no significant associations with CKD stage, a significant interaction between 1,25OHD and FokITT was observed (P = 0.008). The positive association between 1,25OHD and eGFR was steeper in FokICT and CC polymorphisms (r = 0.74) than FokITT polymorphisms (r = 0.65).

Conclusions

These results suggest that higher 1,25OHD levels may be associated with better CKD stages in patients with type 2 diabetes and that this association was modified by FokI polymorphisms.     

Vitamin D Insufficiency is Associated With Reduced Parasympathetic Nerve Fiber Function in Type 2 Diabetes

ObjectiveVitamin D insufficiency is prevalent in subjects with type 2 diabetes mellitus (T2DM) and is associated with peripheral neuropathy. However, there are little data regarding vitamin D status in patients with cardiovascular autonomic neuropathy. Our objective was to evaluate the association of cardiovascular autonomic function, 25-hydroxyvitamin D (25[OH]D) insufficiency (i.e., levels < 30 ng/mL), and multiple metabolic parameters in subjects with T2DM.MethodsWe examined 50 individuals with T2DM. Cardiovascular autonomic function (i.e., parasympathetic function) was assessed by RR-variation during deep breathing (i.e., mean circular resultant [MCR] and expiration/inspiration [E/I] ratio). Metabolic parameters included measures of adiposity, glycemic control, insulin resistance, calcium metabolism, and 25(OH)D.ResultsParticipants with 25(OH)D insufficiency (n = 26) were younger (66 ± 9 vs. 60 ± 10 years, P < .05), more insulin resistant, had a higher body mass index (BMI) and lower adiponectin levels. The MCR (39.5 ± 26.3 vs. 27.6 ± 17.2, P < .01) and E/I ratio (1.21 ± 0.17 vs. 1.15 ± 0.09, P < .01) were lower for those with 25(OH)D insufficiency after controlling for age. A stepwise selection procedure regressing MCR and E/I ratio on a number of metabolic parameters resulted in a model identifying age and 25(OH)D insufficiency as significant determinants for both measures. The interaction of age × 25(OH)D insufficiency was also included (MCR model, R² = 0.491, P < .001; E/I ratio, R² = 0.455, P < .001). Neither glycemic control nor other metabolic parameters were selected.ConclusionOur results suggest that 25(OH)D insufficiency is associated with reduced parasympathetic function, with a stronger association in younger persons with T2DM. Studies are needed to determine if vitamin D supplementation into the sufficient range could prevent or delay the onset of cardiovascular autonomic dysfunction. (Endocr Pract. 2015;21:174-181)     

利拉鲁肽治疗2型糖尿病的临床研究进展

利拉鲁肽是一种新型胰高糖素样肽-1 GLP-1类似物,能迅速、高效、持久地降低血糖及糖化血红蛋白,具有改善胰岛β细胞功能、调节收缩压、保护心血管、降低血脂、减轻体重、延迟胃排空、增加饱腹感等作用。此外,利拉鲁肽具有葡萄糖依赖的促胰岛素分泌作用,仅在机体血糖水平高时刺激胰岛素的释放,但当患者体内血糖浓度恢复至正常时,GLP-1分泌促胰岛素的作用便消退,因而发生低血糖事件的几率较低,能有效地改善糖尿病患者的病情,已成为目前2型糖尿病治疗领域的研究热点。本文主要就利拉鲁肽治疗2型糖尿病的临床研究进展进行综述。